CV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CapsoVision Inc (CV) does not present a strong buy opportunity for a beginner, long-term investor at this moment. While the company has shown positive revenue and net income growth, the lack of clear technical buy signals, neutral trading sentiment, and absence of recent news or significant catalysts suggest that waiting for further developments or a more favorable entry point may be prudent.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 44.883, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 5.113, with resistance at 5.556 and support at 4.67. Overall, technical indicators suggest a neutral trend.
The company has submitted a 510(k) application to the FDA for its proprietary AI-assisted module, which could be a future growth driver. Analysts have raised the price target significantly from $5 to $14, citing competitive advantages in AI and clinical data.
Gross margin has dropped by 3.17% YoY, and the company is still operating at a net loss of -$7.92 million. There is no recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q3 2025, revenue increased by 19.29% YoY to $3.54 million, net income improved by 36.71% YoY to -$7.92 million, and EPS increased by 30.77% YoY to -0.17. However, gross margin dropped to 54.1%, down 3.17% YoY.
Benchmark raised the price target from $5 to $14 and maintains a Speculative Buy rating, citing competitive advantages in AI and data-driven growth potential.
